«Adjuvant
Ipilimumab effects survival after high risk lymph node and melanoma resection.»
Not exact matches
Indeed, the authors point out that
Ipilimumab might better
effect recurrence - free survival than adjuvant interferon and should be considered as an option by oncologists in this field considering its activity across subgroups including those with high tumor burden.
In addition, combining the anti-RANKL antibody with
ipilimumab produced a synergistic
effect and helped prolong survival.
Patients in the clinical trial who got the combined therapies also had fewer serious adverse side
effects than those who received only
ipilimumab, the researchers report in the Journal of the American Medical Association.
Hodi designed this investigator - initiated clinical trial to find out if giving sargramostim along with
ipilimumab would have a synergistic
effect against the melanoma — like pressing the immune system's accelerator while releasing the brake.
They studied the
effects of this treatment in combination with
ipilimumab, a U.S. Food and Drug Administration - approved immunotherapy.
«But this opens the possibility of improving clinical outcomes and decreasing serious side
effects in treating advanced melanoma with
ipilimumab.»
«Combined checkpoint inhibitor treatments, such as
ipilimumab - nivolumab, have produced higher response rates, but they can have serious side
effects.
A second study — from the Institut Gustave Roussy in Paris, published in the same issue of Science — found that antibiotics could disrupt the antitumor
effects of
ipilimumab.
«The side
effects were quite high with the combination, with about 30 % of patients discontinuing due to treatment - related adverse events, as compared to 5 % with nivolumab and 13 % for
ipilimumab.»
Advanced melanoma patients successfully treated with a combination of nivolumab and
ipilimumab may endure severe side
effects, but they do not suffer any clinically meaningful changes in health - related quality of life.